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nated: rivaroxaban and dabigatran 150mg. The efficiency frontier was constructed 
by connecting the remaining strategies: warfarin and apixaban. Apixaban resulted 
in an incremental additional cost of 2,870€ and an incremental QALY of 0.189, cor-
responding to an ICER of 15,157€ /QALY versus warfarin. The PSA indicated that the 
probabilities for apixaban being cost-effective versus warfarin were respectively 80% 
and 90% at the informal willing-to-pay thresholds of 30,000€ and 50,000€ . Sensitivity 
analysis identified stroke risk with apixaban and intracranial hemorrhage risk with 
warfarin as the variables most influencing the results. ConClusions: Apixaban 
may be the most economically efficient alternative to warfarin in NVAF patients 
eligible for stroke prevention in France. All other strategies are dominated. However, 
uncertainty surrounding these results should be investigated through real life data.
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objeCtives: Heart failure is quite common in elderly patients with type 2-diabetes. 
Screening could potentially improve health outcomes at acceptable costs through 
early detection and adherence to current prescription guidelines. Based on a pro-
spective study the cost-effectiveness of different screening strategies to detect heart 
failure in patients aged 60 years with type 2-diabetes was assessed. Methods: 
Data obtained from our prospective study and literature were used in a Markov 
model with a lifetime horizon to evaluate the incremental cost-effectiveness ratio 
of five increasingly extensive screening strategies. Differences in survival rates 
estimated by the Seattle Heart Failure Model between patients with undetected 
versus detected heart failure, induced by medication use, were used to adjust input 
parameters for health states related to undetected heart failure. Estimates for costs, 
utilities, and transition probabilities were additionally adjusted to age and NYHA 
class. Scenario analyses were performed to evaluate the impact of screening age 
and medication prescription and effectiveness. Probabilistic sensitivity analysis 
was performed to assess robustness of the results. Results: For both men and 
women usual care (no screening) had the highest probability of being cost-effective 
when the willingness to pay (WTP) was small. For WTP values in the range of € 4,600/
QALY-€ 27,000/QALY for men and € 5,200/QALY-€ 40,000/QALY for women evaluation 
of the electronic medical record and symptoms had the highest probability of 
being cost-effective. For higher WTP values echocardiography was the preferred 
strategy. For all screening strategies cost-effectiveness improved if prescription of 
heart failure medication was optimal or screening was started at the age of 70 
years. ConClusions: Screening for heart failure through evaluation of electronic 
medical record and symptoms has favorable cost-effectiveness and echocardiog-
raphy may also be acceptable at higher WTP values. The benefits from screening 
could be much larger than currently identified when test outcomes would more 
often lead to proper medication prescription.
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objeCtives: To assess the cost-effectiveness of apixaban versus rivaroxaban in 
the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in 
Spain. Methods: A Markov model was developed to simulate the evolution of 
NVAF patients throughout their lifetime. Cycle’s length was 6 weeks and 10 health 
states such as stroke, bleeding and other cardiovascular complications were defined. 
Drug’s safety and efficacy outcomes were obtained from a meta-analysis of pairwise 
indirect comparisons. The analysis was made from the Spanish National Health 
System (NHS) and the societal perspective. Apixaban and rivaroxaban pharmaco-
logical costs were calculated according to their recommended doses (5 mg twice 
daily (BID) and 20 mg once-a-day (QD), respectively). The cost of NVAF complications 
and disease management were obtained from Spanish sources. An annual discount 
rate of 3.5% for costs and health outcomes was applied. Results: Model results 
illustrate that 1,000 patients with NVAF treated with apixaban during their lifetime 
could avoid numerous complications versus rivaroxaban (9 strokes, 10 intracranial 
bleedings, 1 systemic embolism, 32 major bleedings, 52 clinically relevant non major 
bleedings and 12 related deaths). The use of apixaban was associated with 0.062 life 
years (LYG) and 0.049 quality-adjusted life-years (QALYs) gained when compared to 
rivaroxaban. Due to the lower expected mortality of patients, apixaban generated 
more costs per patient vs. rivaroxaban from the NHS perspective (115 € ), but savings 
would arise from the societal perspective (-241 € ). Incremental cost-effectiveness 
ratio results were 1,855 € per LYG and 2,347 € per QALY gained for the NHS analysis. 
Apixaban was dominant (more effective and less costly than rivaroxaban) from the 
societal perspective. Deterministic and probabilistic sensitivity analyses confirmed 
these results. ConClusions: According to this analysis, apixaban is a cost-effective 
treatment compared with rivaroxaban for the prevention of stroke in patients with 
NVAF in Spain.
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objeCtives: To calculate treatment costs for patients hospitalised for heart fail-
ure (HF) and analyse associated medical resource utilisation in a real-life care set-
ting. Methods: The study was designed as a retrospective medical record review of 
a cohort of 478 patients diagnosed and hospitalised for HF (as the primary diagnosis 
for hospitalisation with ICD-10 codes I11, I13 and I50 meeting the inclusion and 
exclusion criteria of RELAX-AHF, a randomised, placebo-controlled phase III-trial 
in acute HF) in three German hospitals. Costs and medical resource utilisation for 
HF treatment were extracted from datasets according to §21 KHEntgG (Hospital 
Reimbursement Act) and patient medical records from the full year of 2011. Costs 
of HF treatment were determined according to the cost calculation scheme of the 
German Institute for the Hospital Remuneration System (InEK). A multivariate 
regression model was developed to detect incremental effects. Results: The mean 
cost per hospital stay was 3,518 € [3,203 € ; 3,833 € ; 95%CI 315 € ]. Differences in costs 
between male and female patients were not significant. The mean length of stay 
(LOS) was 8.55 days [8.0; 9.1; 95%CI 0.55] with in-hospital mortality being 5.4% (26 
of 478 patients). A total of 637 different active pharmaceutical agents and agent 
combinations were used. The percentage of patients treated with loop diuretics 
was 84%. About 8% of patients received nitrates (all formulations). The regression 
model showed a positive correlation for treatment costs with LOS and the amount 
of daily drug doses. ConClusions: This analysis highlights that HF is a condition 
that imposes considerable costs to the German health care system. Data suggests 
that there is a high use of diuretics and a low use of nitrates in a real-life care setting.
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objeCtives: To assess the cost-effectiveness of apixaban vs. dabigatran in 
stroke prevention in patients with non-valvular atrial (NVAF) fibrillation in 
Spain. Methods: A Markov model was developed, with cycles of 6 weeks, through-
out the patient’s life and 10 health states. The analysis was made from the Spanish 
National Health System (NHS) and the societal perspective. The safety and efficacy 
of the drugs was obtained from a meta-analysis of pairwise indirect comparisons. 
Drug costs, (apixaban: 5 mg twice daily (BID); dabigatran: 110 mg BID or 150 mg 
BID), NVAF complications and disease management costs were obtained from 
Spanish sources. An annual discount rate of 3.5% for costs and health outcomes 
was applied. Results: In a cohort of 1,000 patients with NVAF, apixaban could 
avoid numerous complications versus dabigatran during their lifetime (24 ischemic 
strokes and 28 related deaths vs. dabigatran 110 mg; 11 ischemic strokes, 29 bleed-
ings and 19 deaths vs. dabigatran 150 mg). The use of apixaban was associated with 
0.126 life years (LYG) and 0.107 quality-adjusted life-years (QALYs) gained when 
compared to dabigatran 110 and 150 mg, respectively. Apixaban was estimated to 
generate more costs per patient vs. dabigatran 110 mg from the NHS perspective 
(139 € ) but overall savings could arise from the societal perspective (-524 € ), with a 
cost per QALY gained of 1,299 € for the NHS. Apixaban was dominant (more effective 
and less costly than dabigatran 110 mg) from the societal perspective. The cost per 
QALY gained, from the NHS and societal perspective, compared with dabigatran 
150 mg BID was 6,591 € and 10,676 € , respectively. Deterministic and probabilistic 
sensitivity analyses confirmed the stability of these results. ConClusions: Results 
suggest that apixaban is cost-effective versus dabigatran for the prevention of stroke 
in patients with NVAF in Spain.
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objeCtives: To evaluate the cost-effectiveness of apixaban in the prevention of 
stroke in patients with non-valvular atrial fibrillation (NVAF) from a French payer 
perspective. Methods: A Markov model was developed in accordance to the new 
French guidelines of the Commission for Economic Evaluation and Public Health 
(CEESP) that also recommends applying efficiency frontier. A hypothetical cohort of 
patients with NVAF, 70 years old eligible for stroke preventive treatment (CHADS2≥ 1) 
was simulated over lifetime. Clinical events modeled included strokes, systemic 
embolism, intracranial hemorrhage, other major bleeds, clinically relevant non-
major bleeds and myocardial infarction. Treatment efficacy and bleeding data was 
obtained from ARISTOTLE. Efficacy data are from published indirect comparisons. 
Acute medical costs of stroke and hemorrhage were obtained from a dedicated 
analysis of the French national hospitalization database (PMSI). Long-term medical 
costs and utility data were derived from the literature. Univariate and probabilistic 
sensitivity analyses (PSA) were also performed to assess the robustness of the model 
projections. Results: Three strategies were strictly dominated: aspirin, dabigatran 
110mg, and dabigatran in sequential dosages. Two others were extendidly domi-
